drugset / Trial / NCT06496607
A Study to Evaluate Solriktug in Adult Participants With Asthma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Timeline
- Start
- 2024-07-26
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solrikitug | Monoclonal antibody | — | Subcutaneous |